| Vicki Claymon, | |
|
6314 Kerryhill Ct, Agoura Hills, CA 91301-4115 | |
| (818) 268-7693 | |
| Not Available |
| Full Name | Vicki Claymon |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 6314 Kerryhill Ct, Agoura Hills, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558644120 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 8513 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Vicki Claymon, 6314 Kerryhill Ct, Agoura Hills, CA 91301-4115 Ph: () - | Vicki Claymon, 6314 Kerryhill Ct, Agoura Hills, CA 91301-4115 Ph: (818) 268-7693 |
News Archive
The protein Oct-6 is not a biological marker for schizophrenia. The results of a study published today in the open access journal BMC Psychiatry contradict previous findings and show that Oct-6, a protein involved in neurodevelopment, is normally expressed in the adult brain and cannot be used to identify patients with schizophrenia.
Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
An increase in women with breast cancer choosing double mastectomy may be influenced by media coverage of celebrities, a new study finds.
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.
Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis.
› Verified 9 days ago
Taryn Reitman, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4258 Via Mira Monte, Agoura Hills, CA 91301 Phone: 818-309-3420 | |
Denise Zweig, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5627 Kanan Rd Ste 184, Agoura Hills, CA 91301 Phone: 805-262-7809 | |
Tina Valcarenghi, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5236 Colodny Dr, Suite #205, Agoura Hills, CA 91301 Phone: 818-865-8135 | |
Amy Simon-weiner, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5520 Fairgrange Dr, Agoura Hills, CA 91301 Phone: 818-991-4314 | |
Siri Ilene Woods, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 29120 Quail Run Dr, Agoura Hills, CA 91301 Phone: 818-631-8410 | |
Chris Byers, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5012 Chesebro Rd, Suite 101, Agoura Hills, CA 91301 Phone: 818-419-1123 |